{
  "docId": "019de076-9d2b-76a8-843e-6686f2efe993",
  "docSlug": "264dd70dbc5f8f6fdd2a3dbf6f8c09b5",
  "documentTitle": "Exscientia | Investor Day Presentation Deck | 90 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 60,
  "pageCount": 90,
  "prevPage": 59,
  "nextPage": 61,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide highlights the potential for '539 to address brain metastases in SCLC patients.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9d2b-76a8-843e-6686f2efe993/60",
  "deckHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993",
  "deckJsonHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993.json",
  "deckAnchorHref": "/decks/019de076-9d2b-76a8-843e-6686f2efe993#slide-60",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.42,
        "y": 0.26
      },
      "kind": "callout",
      "text": "Brain metastases develop in ~50% of SCLC patients. '539, a brain penetrant molecule, may target brain metastases as well as peripheral disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b0968643-e30a-48f8-8856-8378a43156ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.3,
        "x": 0.28,
        "y": 0.23
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0515f3df-b7c7-4484-99e4-f5fd914f14e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.05,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "metric",
      "text": "28K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22c9bb39-b0ad-4005-89d1-d2de4c49e9cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.68,
        "y": 0.46
      },
      "kind": "metric",
      "text": "~45K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35f7382c-08c7-4570-9a13-69d7a8caae60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.05,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "metric",
      "text": "17K",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a2aabde-33f6-4f43-b507-d7a767d10b87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.85,
        "y": 0.49
      },
      "kind": "paragraph",
      "text": "U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6be1e28e-1b52-40fa-b897-9b0e3d4e813b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Small-cell Lung Cancer Extensive Disease (Stage III / IV)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce37bb70-e30a-4f46-af59-7fa45304e7d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.07,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Acute Myeloid Leukaemia",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbcdf06e-d306-45fa-8f3f-9919703aefb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Covers all indications currently being prioritised for IND/CTA-enabling studies. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; 1) Li et al. Int J Gen Med, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "835a5a8c-0a6a-4f0a-8b27-cc74562b31a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for planned patient sub-groups",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46569050-2838-4973-bcad-6c98e69ae3bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "LSD1: '539 IND-enabling studies complete",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4384ec7a-bd2b-4925-a865-5406974625d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 90,
      "from": 21,
      "beatId": "08c298bd-8dc4-4aa8-832d-c7b35097d152",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The presentation deck ends with a call to action, encouraging investors to take action",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}